• Home
• People
• Bio
• Paul Adams

Paul Adams

Dr. Adams received his medical degree from Queen’s University, Canada in 1980. After completing an internship and residency training in Toronto, he did further training at Mount Sinai Hospital, New York and completed a Fellowship in Gastroenterology at the University of California at San Francisco (UCSF).  He also worked at the Liver Research Unit of the Royal Brisbane Hospital, Australia.  He is currently Professor in the Division of Gastroenterology at the Western University in London, Canada. His research interest is the study of genetic hemochromatosis.

Selected Publications

Adams PC, Speechley M, Barton J, McLaren C, McLaren G, Eckfeldt J. Probability of C282Y-linked hemochromatosis decreases as liver transaminase activities increase in participants with hyperferritinemia in the HEIRS study. Hepatology 2012;55:1722-1726.

Adams PC, Barton JC. How I treat hemochromatosis. Blood 2010;116:317-325.

Adams PC, Barton JC. Haemochromatosis. Lancet 2007;370:1855-60.

Adams PC, Reboussin D, Barton J, et al. Hemochromatosis and Iron-Overload Screening of a racially diverse population. N Eng J Med 2005;372:17-30.

Jeffrey G, Chakrabarti S, Hegele RA, Adams PC. Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. Nature Genetics 1999;22:325-326.

Acton RT, Snively BM, Barton JC, McLaren CE, Adams PC, Rich SS, Eckfeldt JH, Press RD, Sholinsky P, Leiendecker-Foster C, McLaren GD, Speechley MR, Harris EL, Dawkins FW, Gordeuk VR. A genome-wide search for hemochromatosis susceptibility loci. Clinical Genetics 2007;71:518-529.

Adams PC, Passmore L, Chakrabarti S, Reboussin D, Acton R, Barton J, McLaren G, Eckfeldt J, Dawkins F, Gordeuk V, Harris E, Leiendecker-Foster C, Gossman E, Sholinsky P. Liver diseases in participants in the Hemochromatosis and Iron Overload Screening Study. Clin Gastro Hepatology 2006;4:918-923.

Adams PC, Pankow J, Barton JC, Acton RT, Leiendecker- Foster C, McLaren GD,Speechley M, Eckfeldt J. HFE C282Y homozygosity is associated with lower total and LDL cholesterol: the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Circulation: Cardiovascular Genetics 2009;2:34-37.

Bacon BR, Adams PC, Kowdley K, Powell LW, Tavill AS. Diagnosis and Management of Hemochromatosis: AASLD Practice Guidelines. Hepatology 2011;54:328-343.

Adams PC, Speechley M, Barton J, McLaren C, McLaren G, Eckfeldt J. Probability of C282Y-linked hemochromatosis decreases as liver transaminase activities increase in participants with hyperferritinemia in the HEIRS study. Hepatology 2012;55:1722-1726.

Beaton M, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams PC. Phase II Clinical Trial of Phlebotomy Therapy for non-alcoholic liver disease. Alimentary Pharmacology and Therapeutics 2013;37:720-729.

Beaton M, Chakrarbti S, Adams PC. Inflammation is not the cause of an elevated serum ferritin in Non-Alcoholic Fatty Liver Disease. Annals Hepatology 2014;13:353-356.

Lim A, Speechley M, Adams PC. Predicting C282Y homozygote genotype for hemochromatosis using serum ferritin and transferrin saturation in 44,809 participants from the HEIRS study. Can J Gastro Hep 2014;28:505-509.

McLaren CE, Emond MJ, Subramaniam VN, Phatak PD, Barton JC, Adams PC, Goh JB,McDonald CJ, Powell LW, Gurrin LC, Allen KJ, Nickerson DA, Louie T, Ramm GA,Anderson GJ, McLaren GD. Exome sequencing in HFE C282Y homozygous men with extreme phenotypes identifies a GNPAT variant associated with severe Iron overload. Hepatology 2015;62:429-439